 |
|
Neurologix announces positive results of gene therapy clinical trial in Parkinson's disease
September 26, 2005Investigators report safety findings and statistically significant improvements in clinical measures of movement, PET Scans at 19th Annual Symposia on the Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders
Neurologix's Phase I trial showed positive interim results in patients with Parkinson's disease. One year following treatment, patients exhibited a statistically significant improvement in motor function on the side of their body correlating to the treated part of the brain. Further, PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, results considered similar to those achieved with STN Deep Brain Stimulation.
FORT LEE, N.J. - Neurologix, Inc. (OTCBB:NRGX) today announced positive interim results of its landmark gene therapy clinical trial for patients with Parkinson's disease. Neurologix's 12-patient, dose-escalating Phase I trial is the world's first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult neurological disease. In the Neurologix-funded trial, the vector was injected into a specific target site in the brain in order to transfer a gene to treat Parkinson's disease. The gene encodes glutamic acid decarboxylase (GAD), an enzyme which synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA).
Under the FDA-sanctioned trial protocol, patients with advanced Parkinson's disease received unilateral (one side of the brain) infusion of AAV-GAD via a hair-thin catheter into the subthalamic nucleus (STN), a deep brain structure known to function abnormally in Parkinson's patients. According to the interim findings, Neurologix's STN AAV-GAD treatment appears to be safe and well-tolerated in advanced Parkinson's disease, with no evidence of adverse effects or immunologic reaction related to the study treatment. Furthermore, patients in the trial, at one year, exhibited a statistically significant improvement (27%, p = .04) in motor function on the side of their body correlating to the treated part of the brain, as measured by the Unified Parkinson Disease Rating Scale (UPDRS). In contrast, the untreated side evidenced no significant improvement in the UPDRS score. Also, activities of daily living (ADL), another standard measure of Parkinson's severity which is recorded by the patients themselves, showed a strong trend toward statistical improvement (p= .06).
In addition, fluorodeoxyglucose (FDG)-PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, while the untreated side showed a further increase in abnormal metabolism. The imaging results were considered similar to those achieved with STN Deep Brain Stimulation, an FDA-approved treatment which currently represents the preferred surgical approach for advanced Parkinson's disease. This data provides solid biological support for the observed clinical improvements.
Twelve subjects in total have undergone gene transfer, four in each of three dose cohorts. Seven of the eight patients representing the low and mid-dose cohorts have now been evaluated one year following treatment. Three of the remaining five subjects have been followed for six months and the remaining two for more than four months.
The trial results were presented by Andrew Feigin, M.D., Associate Director, Movement Disorders Center of the North Shore-Long Island Jewish Health System at the 19th Annual Symposia on the Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Dr. Feigin and his colleague David Eidelberg, M.D., Head of the Neurosciences Research Center at North Shore, have been responsible for monitoring, evaluating and conducting neurological reviews of the trial participants before and for one year following treatment.
The gene therapy procedures were performed at NewYork-Presbyterian Hospital/Weill Cornell Medical Center by Michael G. Kaplitt, M.D., Ph.D., the Tara and Victor Menezes Clinical Scholar in Neurosurgery at Weill Cornell Medical College and Director of Stereotactic and Functional Neurosurgery at NewYork-Presbyterian/Weill Cornell, and Dr. Matthew J. During, Professor of Molecular Medicine at the University of Auckland. Drs. Kaplitt and During are the co-founders of Neurologix and are consultants to the company. In a joint statement, Drs. Kaplitt and During commented: "While the primary objective of any Phase I trial is to demonstrate safety, the FDA's requirement of unilateral infusion of AAV-GAD allowed us the unique opportunity to compare treated and untreated sides of the brain. In essence, the untreated side acted as a control. The combined clinical and imaging data provide powerful evidence that this treatment appears to be efficacious, as well as safe, at the current dose levels."
This Phase I trial is the culmination of more than 10 years of basic research. In 1994, Dr. Kaplitt was the first author of a paper published in Nature Genetics, along with Dr. During as senior author, which demonstrated, for the first time in a preclinical model, that AAV could be a safe and effective vehicle for gene therapy in the brain. Most importantly, AAV has never been associated with any human disease.
According to Drs. Kaplitt and During, "The goal of this research is to determine whether we can 're-set' a specific group of cells that have become overactive, causing the characteristic impaired movements associated with Parkinson's disease. The interim UPDRS scores are highly promising and, if they are borne out with additional data, would be comparable to results seen with STN Deep Brain Stimulation. Unlike deep brain stimulation, however, our gene therapy approach is much simpler, can be carried out entirely under local anesthesia, and avoids leaving any devices in the body. We look forward to the completion of the patient evaluations and the final analysis of these findings." Under the clinical protocols, the last cohort of patients was treated this past spring and will complete evaluations by mid-2006. Pending the final results, Neurologix intends to formulate and submit to the FDA a pivotal trial protocol for the use of STN AAV-GAD in the treatment of Parkinson's disease.
"The results of the trial are highly encouraging, in terms of both safety and efficacy," stated Eric J. Nestler, M.D., Ph.D., member of the Neurologix Scientific Advisory Board and Professor and Chairman, Lou and Ellen McGinley Distinguished Chair in Psychiatric Research, The University of Texas Southwestern Medical Center at Dallas. "These are very exciting findings. If the efficacy demonstrated here is replicated in a definitive trial, it would represent a fundamentally new platform for the treatment, not only of Parkinson's disease, but of a large number of neurological and psychiatric disorders as well. Such a replication would make viral-mediated gene therapy for brain diseases a reality."
Dr. Paul Greengard, Nobel Laureate, Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at Rockefeller University, and Chairman of the Neurologix Scientific Advisory Board, commented, "The initial results of the trial are very encouraging. To achieve, in a phase I study, statistically significant improvement in both motor scores and PET scans at one year is impressive, particularly given the absence of these changes on the untreated side of the brain. We look forward, now, to a pivotal trial to even more vigorously test and corroborate these important results."
About the Neurologix Phase I Clinical Trial
The Phase I trial, which is the first FDA-approved clinical trial to test gene therapy to treat Parkinson's disease, is an open-label dose-escalation study with four patients in each of three escalating dose cohorts. The third cohort of four patients received 10 times the dose of the first cohort. The 12 patients participating in the trial were diagnosed with severe Parkinson's disease of at least five years' duration and no longer adequately responded to current medical therapies.
Following treatment, patients were evaluated at 1, 3, 6 and 12 months. These evaluations included scoring via the UPDRS, neuropsychological testing, videotaped examinations and timed motor tasks. PET scans were also taken at baseline, 6 and 12 months.
The Gene Therapy Procedure
The surgery entailed a stereotactic neurosurgical procedure performed under local anesthesia with the patient awake. First, MRI was used to image the target subthalamic nucleus (STN) region of the brain. The STN was mapped using microelectrodes by recording from single neurons as the electrode was slowly moved towards the STN. Once a signature firing pattern was obtained confirming that the electrode was in the STN, the fine-wire electrode was removed, leaving only the microelectrode sheath through which a hair-thin (165 micron) hollow tube was inserted. Thirty-five microliters containing 3.5, 10 or 35 billion particles (depending upon dose cohort) of the AAV (adeno-associated virus) viral vector with a human GAD gene (cDNA) were then infused at 0.5 microliters/minute, together with 15 microliters of 25% mannitol. After the 100-minute infusion period, the delivery catheter was withdrawn and the incision closed. No hardware was left behind following this procedure, and all patients were discharged within 48 hours of the procedure.
About Neurologix
Neurologix, Inc. is a development-stage company, which through its subsidiary, Neurologix Research, Inc., is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, primarily utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease and epilepsy and its core technology, which it refers to as "NLX," is currently being tested in a Company-sponsored Phase I human clinical trial to treat Parkinson's disease.
Burns McClellan
Under the FDA-sanctioned trial protocol, patients with advanced Parkinson's disease received unilateral (one side of the brain) infusion of AAV-GAD via a hair-thin catheter into the subthalamic nucleus (STN), a deep brain structure known to function abnormally in Parkinson's patients. According to the interim findings, Neurologix's STN AAV-GAD treatment appears to be safe and well-tolerated in advanced Parkinson's disease, with no evidence of adverse effects or immunologic reaction related to the study treatment. Furthermore, patients in the trial, at one year, exhibited a statistically significant improvement (27%, p = .04) in motor function on the side of their body correlating to the treated part of the brain, as measured by the Unified Parkinson Disease Rating Scale (UPDRS). In contrast, the untreated side evidenced no significant improvement in the UPDRS score. Also, activities of daily living (ADL), another standard measure of Parkinson's severity which is recorded by the patients themselves, showed a strong trend toward statistical improvement (p= .06).
In addition, fluorodeoxyglucose (FDG)-PET scans at one year revealed that the treated side of the brain exhibited a statistically significant decrease in abnormal metabolism, while the untreated side showed a further increase in abnormal metabolism. The imaging results were considered similar to those achieved with STN Deep Brain Stimulation, an FDA-approved treatment which currently represents the preferred surgical approach for advanced Parkinson's disease. This data provides solid biological support for the observed clinical improvements.
Twelve subjects in total have undergone gene transfer, four in each of three dose cohorts. Seven of the eight patients representing the low and mid-dose cohorts have now been evaluated one year following treatment. Three of the remaining five subjects have been followed for six months and the remaining two for more than four months.
The trial results were presented by Andrew Feigin, M.D., Associate Director, Movement Disorders Center of the North Shore-Long Island Jewish Health System at the 19th Annual Symposia on the Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Dr. Feigin and his colleague David Eidelberg, M.D., Head of the Neurosciences Research Center at North Shore, have been responsible for monitoring, evaluating and conducting neurological reviews of the trial participants before and for one year following treatment.
The gene therapy procedures were performed at NewYork-Presbyterian Hospital/Weill Cornell Medical Center by Michael G. Kaplitt, M.D., Ph.D., the Tara and Victor Menezes Clinical Scholar in Neurosurgery at Weill Cornell Medical College and Director of Stereotactic and Functional Neurosurgery at NewYork-Presbyterian/Weill Cornell, and Dr. Matthew J. During, Professor of Molecular Medicine at the University of Auckland. Drs. Kaplitt and During are the co-founders of Neurologix and are consultants to the company. In a joint statement, Drs. Kaplitt and During commented: "While the primary objective of any Phase I trial is to demonstrate safety, the FDA's requirement of unilateral infusion of AAV-GAD allowed us the unique opportunity to compare treated and untreated sides of the brain. In essence, the untreated side acted as a control. The combined clinical and imaging data provide powerful evidence that this treatment appears to be efficacious, as well as safe, at the current dose levels."
This Phase I trial is the culmination of more than 10 years of basic research. In 1994, Dr. Kaplitt was the first author of a paper published in Nature Genetics, along with Dr. During as senior author, which demonstrated, for the first time in a preclinical model, that AAV could be a safe and effective vehicle for gene therapy in the brain. Most importantly, AAV has never been associated with any human disease.
According to Drs. Kaplitt and During, "The goal of this research is to determine whether we can 're-set' a specific group of cells that have become overactive, causing the characteristic impaired movements associated with Parkinson's disease. The interim UPDRS scores are highly promising and, if they are borne out with additional data, would be comparable to results seen with STN Deep Brain Stimulation. Unlike deep brain stimulation, however, our gene therapy approach is much simpler, can be carried out entirely under local anesthesia, and avoids leaving any devices in the body. We look forward to the completion of the patient evaluations and the final analysis of these findings." Under the clinical protocols, the last cohort of patients was treated this past spring and will complete evaluations by mid-2006. Pending the final results, Neurologix intends to formulate and submit to the FDA a pivotal trial protocol for the use of STN AAV-GAD in the treatment of Parkinson's disease.
"The results of the trial are highly encouraging, in terms of both safety and efficacy," stated Eric J. Nestler, M.D., Ph.D., member of the Neurologix Scientific Advisory Board and Professor and Chairman, Lou and Ellen McGinley Distinguished Chair in Psychiatric Research, The University of Texas Southwestern Medical Center at Dallas. "These are very exciting findings. If the efficacy demonstrated here is replicated in a definitive trial, it would represent a fundamentally new platform for the treatment, not only of Parkinson's disease, but of a large number of neurological and psychiatric disorders as well. Such a replication would make viral-mediated gene therapy for brain diseases a reality."
Dr. Paul Greengard, Nobel Laureate, Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at Rockefeller University, and Chairman of the Neurologix Scientific Advisory Board, commented, "The initial results of the trial are very encouraging. To achieve, in a phase I study, statistically significant improvement in both motor scores and PET scans at one year is impressive, particularly given the absence of these changes on the untreated side of the brain. We look forward, now, to a pivotal trial to even more vigorously test and corroborate these important results."
About the Neurologix Phase I Clinical Trial
The Phase I trial, which is the first FDA-approved clinical trial to test gene therapy to treat Parkinson's disease, is an open-label dose-escalation study with four patients in each of three escalating dose cohorts. The third cohort of four patients received 10 times the dose of the first cohort. The 12 patients participating in the trial were diagnosed with severe Parkinson's disease of at least five years' duration and no longer adequately responded to current medical therapies.
Following treatment, patients were evaluated at 1, 3, 6 and 12 months. These evaluations included scoring via the UPDRS, neuropsychological testing, videotaped examinations and timed motor tasks. PET scans were also taken at baseline, 6 and 12 months.
The Gene Therapy Procedure
The surgery entailed a stereotactic neurosurgical procedure performed under local anesthesia with the patient awake. First, MRI was used to image the target subthalamic nucleus (STN) region of the brain. The STN was mapped using microelectrodes by recording from single neurons as the electrode was slowly moved towards the STN. Once a signature firing pattern was obtained confirming that the electrode was in the STN, the fine-wire electrode was removed, leaving only the microelectrode sheath through which a hair-thin (165 micron) hollow tube was inserted. Thirty-five microliters containing 3.5, 10 or 35 billion particles (depending upon dose cohort) of the AAV (adeno-associated virus) viral vector with a human GAD gene (cDNA) were then infused at 0.5 microliters/minute, together with 15 microliters of 25% mannitol. After the 100-minute infusion period, the delivery catheter was withdrawn and the incision closed. No hardware was left behind following this procedure, and all patients were discharged within 48 hours of the procedure.
About Neurologix
Neurologix, Inc. is a development-stage company, which through its subsidiary, Neurologix Research, Inc., is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, primarily utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease and epilepsy and its core technology, which it refers to as "NLX," is currently being tested in a Company-sponsored Phase I human clinical trial to treat Parkinson's disease.
Burns McClellan
Parkinsons Disease Current Events and Parkinsons Disease News RSSRutgers Research: Direct Evidence of the Role of Sleep in Memory Formation is Uncovered
A Rutgers University, Newark and Collége de France, Paris research team has pinpointed for the first time the mechanism that takes place during sleep that causes learning and memory formation to occur.
Higher occurrence of Parkinson's linked to low LDL cholesterol
People with low levels of LDL cholesterol are more likely to have Parkinson's disease than people with high LDL levels, according to University of North Carolina at Chapel Hill researchers.
Synchronous neuronal firing may underlie Parkinson's disease
In a finding that contradicts current theories behind Parkinson's disease, neuroscientists at Duke University Medical Center have discovered in mice that critical nerve cells fire all at the same time and thus overwhelm the brain's ability to control the body's movements.
Dopamine imbalances cause sleep disorders in animal models of Parkinson's disease and schizophrenia
Neuroscientists at Duke University Medical Center working with genetically engineered mice have found that the brain chemical dopamine plays a critical role in regulating sleep and brain activity associated with dreaming.
Researchers announce results of study on genetic variation in Parkinson's disease
Researchers at the National Institutes of Health (NIH) have completed one of the first large-scale studies of the role of common genetic variation in Parkinson's disease (PD).
Laser probe of a brain pigment's anatomy may offer insight into Parkinson's disease
In a finding that may offer clues about Parkinson's disease, a team led by Duke University researchers used a sophisticated laser system to gain evidence that a dark brown pigment that accumulates in people's brains consists of layers of two other pigments commonly found in hair.
Two copies of G2019S Parkinson's gene mutation doesn't lead to more severe disease
A group of Parkinson's disease researchers concluded there are no observable differences between those who have two copies of the most common mutation of the recently discovered LRRK2 gene and those who have only one copy.
Government cash injection for University spin-out company's stem cell research
A spin-out company from the University of Nottingham has been awarded around £250,000 of Government funding to develop innovative stem cell therapies that could one day provide new treatments for patients suffering from illnesses including Parkinson's disease and stroke.
Two minutes of magnetic stimulation can change your brain for an hour
A couple of minutes is all it takes to 'knock out' bits of your brain for an hour, according to a new study by a University College London (UCL) team. The team have been working on ways to improve a method known as transcranial magnetic stimulation (TMS) and are now using their adapted version of TMS to investigate possible treatments for stroke patients or those with Parkinson's disease.
Gene therapy shows promise in model of Parkinson's disease
Scientists at the Ecole Polytechnique Federale de Lausanne (EPFL) in Lausanne, Switzerland, have conducted novel experiments that might one day lead to gene therapy treatment options for patients with Parkinson's disease. In research published this week in the Proceedings of the National Academy of Sciences, the research team, led by EPFL President Patrick Aebischer, found that viral delivery of a gene associated with Parkinson's disease protected neurons from degeneration. Parkinson's disease is a progressive, degenerative neurological disorder in which dopamine-producing neurons in the part of the brain responsible for coordinating muscle movement die or become so damaged that they are no
More Parkinsons Disease Current Events and Parkinsons Disease News Articles
 |
Parkinson's Disease: A Complete Guide for Patients and Families, Second Edition (A Johns Hopkins Press Health Book) by William J. Weiner MD (Author), Lisa M. Shulman MD (Author), Anthony E. Lang MD FRCP (Author) Recent innovations, including deep brain stimulation and new medications, have significantly improved the lives of people with Parkinson's disease. Nevertheless, medical, emotional, and physical challenges remain. The second edition of this accessible and comprehensive guide provides crucial information for managing this complex condition, including details on the use of medications, diet, exercise, complementary therapies, and surgery. The second edition includes new information about: • The genetic and hereditary pattern of the disease • Medications and uses of established medications • Other approaches to treating the symptoms of Parkinson's • Juvenile-onset Parkinson's disease • Normal pressure hydrocephalus • The effects of... |
 |
Delay the Disease -Exercise and Parkinson's Disease by David Zid (Author), Jackie Russell (Editor), RN (Editor), BSN (Editor), CNOR (Editor), Photography - Joanne Adams (Editor), BFA (Editor), CMI (Editor) David Zid, an ACE, APG certified trainer, has collaborated with orthopedic surgeon, Thomas H. Mallory, M.D., who is afflicted with Parkinson's disease, in the development of a Parkinson's specific fitness program designed to proactively minimize tremors and improve flexibility, stability, balance and strength. Delay the Disease contains colorful photographs of Zid demonstrating each move, as well as recommendations for exercise frequency, modification and how to adjust the workout as one improves. Parkinson's patients participating in Zid's fitness program notice improvement in walking, dressing and maintaining balance. Exercises are divided into categories (wake up call, walking and balance, cardiovascular, strength, facial and vocal, and night-time stretching. |
 |
Parkinson's Disease for Dummies (Volume 2 of 2) (EasyRead Large Edition) by Michele Tagliati (Author) A diagnosis of Parkinson's disease is a life-altering event. There is no one way to deal with it. Everyone has a unique set of circumstances, and every patient experiences Parkinson's differently. That's why one book on PD can never be all things to all people. Whether you are living with the disease or are a caregiver or friend to someone who is, you will come to rely on a wide variety of high-quality books, manuals, Web sites, resources and tools. You may be surprised by the voracity of your appetite for newer, better, and just plain more information about PD. And since Parkinson's is-for now, at least-a disease that stays with you for life, your information needs may evolve and change over time. This book represents something incredibly important: a place to start. We commend its... |
 |
What Your Doctor May Not Tell You About Parkinson's Disease: A Holistic Program for Optimal Wellness by Jill Marjama-Lyons (Author), Mary J. Shomon (Author) There are over one million people in the U.S. living with Parkinson's disease, a debilitating neurological disorder. Patients can now choose from a variety of increasingly effective treatments, including new drugs, revolutionary surgical techniques, and cutting-edge alternative treatments such as intravenous glutathione therapy. The book covers not only the pros and cons of prescription drug and surgical treatments for Parkinson's, but discusses the latest alternative therapies, including herbal treatments, traditional Chinese medicine, Ayurvedic medicine, diet, exercise, mind-body approaches like Tai Chi, and energy work. With special sections focusing on how patients can deal with persistent problems such as fatigue, depression, and balance problems, and unique chapters that... |
 |
The First Year---Parkinson's Disease: An Essential Guide for the Newly Diagnosed by Jackie Hunt Christensen (Author), Paul, M.D. Tuite (Foreword) Parkinson’s disease—a chronic disorder that causes a progressive loss of nerve cell function in the part of the brain that controls muscle movement—is an incurable neurological condition with debilitating symptoms. Over 1.5 million Americans are affected, and the numbers continue to grow. From the first moment of her Parkinson’s diagnosis, author Jackie Christensen took charge and educated herself on every aspect of her condition. Now, as a "patient-expert," she guides those newly diagnosed step by step through their first year with Parkinson’s. She provides crucial information about the nature of the disease, treatment options, diet, exercise, charts and tables, social concerns, emotional issues, networking with others, and much more. The First Year—Parkinson’s Disease will... |
 |
Parkinson's Disease: 300 Tips for Making Life Easier by Shelley Peterman Schwarz (Author) Being diagnosed with Parkinson's disease can be distressing, and adjusting to the effects of the disease is often difficult. This indispensable resource for patients, family, friends, and caregivers helps patients rise above PD’s challenges by working smarter, maintaining a positive outlook, and conserving time and energy. Organized by subject, the book covers a wide range of topics, including making the home more accessible; dressing aids and simple clothing adaptations; using technology to improve communication; eating and drinking tips for people with difficulty swallowing; mobility and exercise; managing home health care; cars and driving; leisure and recreational activities; travel; and much more. A resource section at the end of each chapter contains contact information for the... |
 |
The Parkinson's Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications by J. Eric Ahlskog M.D. Ph.D. (Author) Nearly one million Americans, including Michael J. Fox and Muhammad Ali, suffer from Parkinson's Disease. Now, a leader in the fight against Parkinson's, Dr. J. Eric Ahlskog of the Mayo Clinic, has written the definitive guide for patients and their families. Dr. Alhskog offers a crystal-clear, nuts-and-bolts approach to the treatment of PD, distilled from over twenty years of experience as a clinician and researcher. His goal is to educate the patient so that they can better team with their doctor to do battle with the disease, streamlining the decision-making process and enhancing their treatment. To do this, Dr. Ahlskog offers a gold mine of information: How do I know if I have PD? What kinds of tests can I take? What medications slow the progress of the disease? What if medications... |
 |
Living Well with Parkinson's Disease: What Your Doctor Doesn't Tell You....That You Need to Know by Gretchen Garie (Author), Michael J. Church (Author), Winifred Conkling (Author) A complete guide to Parkinson's from two people with the disease who cofounded a national support and advocacy organization. In Living Well with Parkinson's Disease, Gretchen Garie and Michael J. Church, a couple who both have Parkinson's and live daily with the effects of the disease, thoroughly discuss diagnosis, treatment options, and the emotional consequences of this difficult illness. With a conversational, pragmatic, and personal tone, they offer advice on such topics as: how Parkinson's disease affects relationships the role of diet, supplements, and rest and relaxation strategies for navigating professional life and the maze of the health-care system handling everyday challenges such as buttoning a shirt or rolling over in bed and more! Compassionate and... |
 |
Stop Parkin' And Start Livin': Reversing the Symptoms of Parkinson's Disease by John C. Coleman (Author) Stop Parkin'and Start Livin': Reversing the Symptoms of Parkinson's Disease is an invaluable resource for those diagnosed with Parkinson's Disease. It provides a plan of action and significant information which the reader can use to return to good health and as an adjunct to working with supportive therapists. |
 |
New Hope for Parkinson's Disease (Home Use) Many times, it can be a difficult task to cope with Parkinson's disease. The primary symptoms of Parkinson's, like tremors and body-rigidity, may be the most obvious but are not always the most disabling. Slowness, stiffness and difficulties with balance can affect a patient's well-being and quality of life as well. In this program, we'll discuss the challenges patients and their families face in dealing with Parkinson's disease. However, by taking a pro-active approach, working with experienced physicians, and cultivating good self-management skills, patients can develop the confidence they need to live well with Parkinson's disease. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
| © 2009 BrightSurf.com |